Myocardial fibrosis induced by exposure to subclinical lipopolysaccharide is associated with decreased miR-29c and enhanced NOX2 expression in mice

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Lew, Wilbur Y W ^a,b   Bayna, Evelyn ^a,b   Dalle Molle, Erminia ^a,b   Contu, Riccardo ^a,b   Condorelli, Gianluigi ^c   Tang, Tong ^a,b  

^a VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; COLLAGEN TYPE 1; COLLAGEN TYPE 1 ALPHA 1; COLLAGEN TYPE 3; COLLAGEN TYPE 3 ALPHA 1; CONNECTIVE TISSUE GROWTH FACTOR; GELATINASE A; GELATINASE B; LIPOPOLYSACCHARIDE; MICRORNA; MICRORNA 29C; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; SODIUM CHLORIDE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSCRIPTION FACTOR RUNX2; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; CELL ADHESION MOLECULE; CYBB PROTEIN, MOUSE; MEMBRANE PROTEIN; MIRN29 MICRORNA, MOUSE; MMP2 PROTEIN, MOUSE; MMP9 PROTEIN, MOUSE; POSTN PROTEIN, MOUSE; TIMP1 PROTEIN, MOUSE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; C57BL 6 MOUSE; CELL ISOLATION; CONTROLLED STUDY; EXPOSURE; FIBROBLAST; GENE EXPRESSION; HEART LEFT VENTRICLE; HEART MUSCLE FIBROSIS; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CARDIOMYOPATHY; CELL CULTURE; CHEMICALLY INDUCED; GENETICS; HEART LEFT VENTRICLE HYPERTROPHY;

MURINAE; MUS;

ANIMALS; CARDIOMYOPATHIES; CELL ADHESION MOLECULES; CELLS, CULTURED; COLLAGEN TYPE I; ENDOMYOCARDIAL FIBROSIS; HYPERTROPHY, LEFT VENTRICULAR; LIPOPOLYSACCHARIDES; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MICRORNAS; NADPH OXIDASE; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 84907212379     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0107556     Document Type: Article

References (48)

1. Manco M, Putignani L, Bottazzo GF (2010) Gut microbiota, lipopolysaccharides, and innate immunity in the pathogenesis of obesity and cardiovascular risk. Endocr Rev 31: 817-844.
2. Wiedermann CJ, Kiechl S, Dunzendorfer S, Schratzberger P, Egger G, et al. (1999) Association of endotoxemia with carotid atherosclerosis and cardiovascular disease: prospective results from the Bruneck Study. J Am Coll Cardiol 34: 1975-1981.
3. Erridge C, Attina T, Spickett CM, Webb DJ (2007) A high-fat meal induces lowgrade endotoxemia: evidence of a novel mechanism of postprandial inflammation. Am J Clin Nutr 86: 1286-1292.
4. Ghanim H, Abuaysheh S, Sia CL, Korzeniewski K, Chaudhuri A, et al. (2009) Increase in plasma endotoxin concentrations and the expression of Toll-like receptors and suppressor of cytokine signaling-3 in mononuclear cells after a high-fat, high-carbohydrate meal: implications for insulin resistance. Diabetes Care 32: 2281-2287.
5. Pussinen PJ, Tuomisto K, Jousilahti P, Havulinna AS, Sundvall J, et al. (2007) Endotoxemia, immune response to periodontal pathogens, and systemic inflammation associate with incident cardiovascular disease events. Arterioscler Thromb Vasc Biol 27: 1433-1439.
6. Niebauer J, Volk HD, Kemp M, Dominguez M, Schumann RR, et al. (1999) Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet 353: 1838-1842.
7. Creely SJ, McTernan PG, Kusminski CM, Fisher fM, Da Silva NF, et al. (2007) Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am J Physiol Endocrinol Metab 292: E740-747.
8. Lew WYW, Bayna E, Molle ED, Dalton ND, Lai NC, et al. (2013) Recurrent exposure to subclinical lipopolysaccharide increases mortality and induces cardiac fibrosis in mice. PLoS ONE 8: e61057.
9. Westermann D, Kasner M, Steendijk P, Spillmann F, Riad A, et al. (2008) Role of left ventricular stiffness in heart failure with normal ejection fraction. Circulation 117: 2051-2060.
10. Bhatia RS, Tu JV, Lee DS, Austin PC, Fang J, et al. (2006) Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 355: 260-269.
11. Komajda M, Lam CS (2014) Heart failure with preserved ejection fraction: a clinical dilemma. Eur Heart J: 35: 1022-1032.
12. Weber KT, Sun Y, Bhattacharya SK, Ahokas RA, Gerling IC (2013) Myofibroblast-mediated mechanisms of pathological remodelling of the heart. Nat Rev Cardiol 10: 15-26.
13. Small EM, Olson EN (2011) Pervasive roles of microRNAs in cardiovascular biology. Nature 469: 336-342.
14. Mendell JT, Olson EN (2012) MicroRNAs in stress signaling and human disease. Cell 148: 1172-1187.
15. Jiang X, Tsitsiou E, Herrick SE, Lindsay MA (2010) MicroRNAs and the regulation of fibrosis. FEBS J 277: 2015-2021.
16. van Rooij E, Olson EN (2009) Searching for miR-acles in cardiac fibrosis. Circ Res 104: 138-140.
17. Pan Z, Sun X, Shan H, Wang N, Wang J, et al. (2012) MicroRNA-101 inhibited postinfarct cardiac fibrosis and improved left ventricular compliance via the FBJ osteosarcoma oncogene/transforming growth factor-beta1 pathway. Circulation 126: 840-850.
18. Seki E, De Minicis S, Osterreicher CH, Kluwe J, Osawa Y, et al. (2007) TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med 13: 1324-1332.
19. Roderburg C, Urban GW, Bettermann K, Vucur M, Zimmermann H, et al. (2011) Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis. Hepatology 53: 209-218.
20. Burgoyne JR, Mongue-Din H, Eaton P, Shah AM (2012) Redox signaling in cardiac physiology and pathology. Circ Res 111: 1091-1106.
21. Maejima Y, Kuroda J, Matsushima S, Ago T, Sadoshima J (2011) Regulation of myocardial growth and death by NADPH oxidase. J Mol Cell Cardiol 50: 408-416.
22. Kim SY, Lee JG, Cho WS, Cho KH, Sakong J, et al. (2010) Role of NADPH oxidase-2 in lipopolysaccharide-induced matrix metalloproteinase expression and cell migration. Immunol Cell Biol 88: 197-204.
23. Ngkelo A, Meja K, Yeadon M, Adcock I, Kirkham PA (2012) LPS induced inflammatory responses in human peripheral blood mononuclear cells is mediated through NOX4 and Giα dependent PI-3kinase signalling. J Inflamm (Lond) 9: 1.
24. Gandhirajan RK, Meng S, Chandramoorthy HC, Mallilankaraman K, Mancarella S, et al. (2013) Blockade of NOX2 and STIM1 signaling limits lipopolysaccharide-induced vascular inflammation. J Clin Invest 123: 887-902.
25. van Rooij E, Sutherland LB, Thatcher JE, DiMaio JM, Naseem RH, et al. (2008) Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci USA 105: 13027-13032.
26. Johar S, Cave AC, Narayanapanicker A, Grieve DJ, Shah AM (2006) Aldosterone mediates angiotensin II-induced interstitial cardiac fibrosis via a Nox2-containing NADPH oxidase. FASEB J 20: 1546-1548.
27. Looi YH, Grieve DJ, Siva A, Walker SJ, Anilkumar N, et al. (2008) Involvement of Nox2 NADPH oxidase in adverse cardiac remodeling after myocardial infarction. Hypertension 51: 319-325.
28. Doerries C, Grote K, Hilfiker-Kleiner D, Luchtefeld M, Schaefer A, et al. (2007) Critical role of the NAD(P)H oxidase subunit p47phox for left ventricular remodeling/dysfunction and survival after myocardial infarction. Circ Res 100: 894-903.
29. Dobaczewski M, Bujak M, Li N, Gonzalez-Quesada C, Mendoza LH, et al. (2010) Smad3 signaling critically regulates fibroblast phenotype and function in healing myocardial infarction. Circ Res 107: 418-428.
30. Duisters RF, Tijsen AJ, Schroen B, Leenders JJ, Lentink V, et al. (2009) miR- 133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling. Circ Res 104: 170-178.
31. Thum T, Gross C, Fiedler J, Fischer T, Kissler S, et al. (2008) MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 456: 980-984.
32. Roy S, Khanna S, Hussain SR, Biswas S, Azad A, et al. (2009) MicroRNA expression in response to murine myocardial infarction: miR-21 regulates fibroblast metalloprotease-2 via phosphatase and tensin homologue. Cardiovasc Res 82: 21-29.
33. Spinale FG (2007) Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev 87: 1285-1342.
34. Kong P, Christia P, Frangogiannis NG (2014) The pathogenesis of cardiac fibrosis. Cell Mol Life Sci 71: 549-574.
35. Thum T (2012) MicroRNA therapeutics in cardiovascular medicine. EMBO Mol Med 4: 3-14.
36. van Rooij E, Olson EN (2012) MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles. Nat Rev Drug Discov 11: 860-872.
37. Small EM, Frost RJ, Olson EN (2010) MicroRNAs add a new dimension to cardiovascular disease. Circulation 121: 1022-1032.
38. Thum T, Catalucci D, Bauersachs J (2008) MicroRNAs: novel regulators in cardiac development and disease. Cardiovasc Res 79: 562-570.
39. Roncarati R, Anselmi CV, Losi MA, Papa L, Cavarretta E, et al. (2013) Circulating miR-29a, among other upregulated microRNAs, is the only biomarker for both hypertrophy and fibrosis in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 63: 920-927.
40. Kriegel AJ, Liu Y, Fang Y, Ding X, Liang M (2012) The miR-29 family: genomics, cell biology, and relevance to renal and cardiovascular injury. Physiol Genomics 44: 237-244.
41. Fang Y, Yu X, Liu Y, Kriegel AJ, Heng Y, et al. (2013) miR-29c is downregulated in renal interstitial fibrosis in humans and rats and restored by HIF-alpha activation. Am J Physiol Renal Physiol 304: F1274-1282.
42. Parker MW, Rossi D, Peterson M, Smith K, Sikstrom K, et al. (2014) Fibrotic extracellular matrix activates a profibrotic positive feedback loop. J Clin Invest 124: 1622-1635.
43. Dangwal S, Thum T (2014) microRNA therapeutics in cardiovascular disease models. Annu Rev Pharmacol Toxicol 54: 185-203.
44. Burgoyne JR, Mongue-Din H, Eaton P, Shah AM (2012) Redox signaling in cardiac physiology and pathology. Circ Res 111: 1091-1106.
45. Zhang M, Perino A, Ghigo A, Hirsch E, Shah AM (2013) NADPH oxidases in heart failure: poachers or gamekeepers? Antioxid Redox Signal 18: 1024-1041.
46. Park HS, Chun JN, Jung HY, Choi C, Bae YS (2006) Role of NADPH oxidase 4 in lipopolysaccharide-induced proinflammatory responses by human aortic endothelial cells. Cardiovasc Res 72: 447-455.
47. Melendez GC, McLarty JL, Levick SP, Du Y, Janicki JS, et al. (2010) Interleukin 6 mediates myocardial fibrosis, concentric hypertrophy, and diastolic dysfunction in rats. Hypertension 56: 225-231.
48. Drummond GR, Selemidis S, Griendling KK, Sobey CG (2011) Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets. Nat Rev Drug Discov 10: 453-471.